# STERIS plc (STE) Stock Analysis: Understanding the 12.55% Upside Potential

- Link: https://www.directorstalkinterviews.com/steris-plc-ste-stock-analysis-understanding-the-12-55-upside-potential/4121261394
- Published: 2026-08-31T10:11:18+01:00
- Author: Madison Wilson

Investors looking for robust opportunities in the healthcare sector might find STERIS
plc (NYSE: STE) an intriguing prospect. With a market capitalization of $22.79 billion,
STERIS plc is a prominent player in the medical devices industry. The company’s 
primary focus on infection prevention products and services positions it well within
a critically important segment of the healthcare market.

Currently trading at $233.78, STERIS plc’s stock has seen a 52-week range between
$199.40 and $268.65. This range suggests a degree of volatility but also indicates
potential for price appreciation. Analysts have set a target price range of $232.00
to $280.00, with an average target of $263.13, representing a potential upside of
12.55%. This makes STERIS an attractive option for investors seeking growth within
the healthcare sector.

Despite the absence of certain valuation metrics like the trailing P/E ratio and
PEG ratio, STERIS’s forward P/E of 19.09 is indicative of growth expectations. The
company’s revenue growth rate of 7.30% further underscores its potential to generate
increasing revenues in the foreseeable future. With an EPS of 8.18 and a return 
on equity of 11.39%, the company demonstrates strong earnings performance and efficient
use of equity capital.

STERIS’s free cash flow stands at an impressive $798.86 million, highlighting its
ability to generate cash after covering operating expenses and capital expenditures.
This financial strength supports its dividend yield of 1.11% with a sustainable 
payout ratio of 30.81%, making it appealing for income-focused investors as well.

The analyst sentiment towards STERIS is predominantly positive, with six buy ratings
and three hold ratings, and notably, no sell ratings. This consensus suggests confidence
in the company’s ability to deliver on its growth projections and maintain its market
position.

From a technical perspective, STERIS’s stock is trading slightly above its 50-day
moving average of $222.92 and very close to its 200-day moving average of $233.72,
reflecting a stable position. The Relative Strength Index (RSI) of 63.04 indicates
that the stock is neither overbought nor oversold, allowing room for further upward
movement. The MACD of 3.28, although below the signal line of 4.21, suggests potential
for bullish momentum as well.

STERIS operates through three segments: Healthcare, Applied Sterilization Technologies,
and Life Sciences. Its comprehensive range of products and services, from sterility
assurance products to surgical tables and sterilizers, caters to a diverse client
base including healthcare providers, medical device manufacturers, and pharmaceutical
facilities.

Founded in 1985 and headquartered in Mentor, Ohio, STERIS has continued to evolve,
most notably rebranding from New STERIS Limited to STERIS plc in 2015. The company’s
strategic focus on infection prevention amid a global emphasis on healthcare safety
positions it strategically within the market.

For investors seeking a blend of growth and income potential in the healthcare sector,
STERIS plc offers an intriguing opportunity. The combination of solid financial 
performance, positive analyst ratings, and a promising market outlook support its
candidacy as a valuable addition to a diversified investment portfolio.

Share on:
